Stock Events

Stock Events

Ovid Therapeutics 

$2.78
113
+$0.07+2.58% Thursday 20:00
+$0.00+0%Thursday 23:30After hours

Statistics

Day High
2.83
Day Low
2.74
52W High
3.11
52W Low
1.12
Volume
56,926
Avg. Volume
-
Mkt Cap
542.93M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.17
-0.13
-0.1
-0.06
Expected EPS
-0.08875
Actual EPS
N/A

Financials

-240.13%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.25MRevenue
-17.41MNet Income

Analyst Ratings

6.67Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OVID. It's not an investment recommendation.
Amazon
24
AMZN
Microsoft
22
MSFT
AMD
20
AMD
Apple
19
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics competes in the rare diseases space, including treatments for neurological disorders, overlapping with Ovid's focus areas.
Biogen
BIIB
Mkt Cap32.28B
Biogen has a strong portfolio in neurology and rare diseases, making it a direct competitor to Ovid Therapeutics.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, including therapies for neurological disorders, competing with Ovid's approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNA interference (RNAi) therapeutics for genetic and rare diseases, including neurological conditions, competing with Ovid.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
Acadia Pharmaceuticals specializes in CNS disorders, including rare neurological conditions, making it a competitor to Ovid.
Anavex Life Sciences
AVXL
Mkt Cap277.16M
Anavex Life Sciences Corp. focuses on developing novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, competing with Ovid.
Neurocrine Biosciences
NBIX
Mkt Cap15.66B
Neurocrine Biosciences targets neurological and endocrine diseases, including treatments that could compete with Ovid's products.

About

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Show more...
CEO
Margaret Alexander
Employees
23
Country
United States
ISIN
US6904691010
WKN
000A2DQ8S

Listings

STU
DE
1OT.STU
MU
DE
1OT.MU
XNAS
US
OVID
F
DE
1OT.F

0 Comments

Share your thoughts

FAQ

What is Ovid Therapeutics stock price today?▼
The current price of OVID is $2.78 USD — it has increased by +2.58% in the past 24 hours. Watch Ovid Therapeutics stock price performance more closely on the chart.
What is Ovid Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ovid Therapeutics stocks are traded under the ticker OVID.
Is Ovid Therapeutics stock price growing?▼
OVID stock has fallen by -0.71% compared to the previous week, the month change is a +9.45% rise, over the last year Ovid Therapeutics has showed a +115.5% increase.
What is Ovid Therapeutics market cap?▼
Today Ovid Therapeutics has the market capitalization of 542.93M
When is the next Ovid Therapeutics earnings date?▼
Ovid Therapeutics is going to release the next earnings report on November 11, 2026.
What were Ovid Therapeutics earnings last quarter?▼
OVID earnings for the last quarter are -0.08 USD per share, whereas the estimation was -0.12 USD resulting in a +30.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ovid Therapeutics revenue for the last year?▼
Ovid Therapeutics revenue for the last year amounts to 7.25M USD.
What is Ovid Therapeutics net income for the last year?▼
OVID net income for the last year is -17.41M USD.
How many employees does Ovid Therapeutics have?▼
As of September 04, 2026, the company has 23 employees.
In which sector is Ovid Therapeutics located?▼
Ovid Therapeutics operates in the Health & Wellness sector.
When did Ovid Therapeutics complete a stock split?▼
Ovid Therapeutics has not had any recent stock splits.
Where is Ovid Therapeutics headquartered?▼
Ovid Therapeutics is headquartered in NEW YORK, United States.